{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:01:34Z","timestamp":1778713294992,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T00:00:00Z","timestamp":1312243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s00432-011-1006-0","type":"journal-article","created":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T07:01:08Z","timestamp":1312182068000},"page":"1463-1468","source":"Crossref","is-referenced-by-count":9,"title":["Lack of association between BARD1 Cys557Ser variant and breast cancer risk: a meta-analysis of 11,870 cases and 7,687 controls"],"prefix":"10.1007","volume":"137","author":[{"given":"Da-Peng","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Feng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Lang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Bo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,2]]},"reference":[{"key":"1006_CR1","doi-asserted-by":"crossref","first-page":"41399","DOI":"10.1074\/jbc.M106551200","volume":"276","author":"PS Brzovic","year":"2001","unstructured":"Brzovic PS, Meza JE, King MC, Klevit RE (2001) BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein\u2013protein interactions. J Biol Chem 276:41399\u201341406","journal-title":"J Biol Chem"},{"key":"1006_CR2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng879","volume":"31","author":"CHEK2 Breast Cancer Consortium","year":"2002","unstructured":"CHEK2 Breast Cancer Consortium (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55\u201359","journal-title":"Nat Genet"},{"key":"1006_CR3","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1086\/426403","volume":"75","author":"C Cybulski","year":"2004","unstructured":"Cybulski C, G\u00f3rski B, Huzarski T et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131\u20131135","journal-title":"Am J Hum Genet"},{"key":"1006_CR4","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1038\/sj.onc.1202717","volume":"18","author":"R Dechend","year":"1999","unstructured":"Dechend R, Hirano F, Lehmann K et al (1999) The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB\/Rel and nuclear co-regulators. Oncogene 18:3316\u20133323","journal-title":"Oncogene"},{"key":"1006_CR5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clini Trials 7:177\u2013188","journal-title":"Control Clini Trials"},{"key":"1006_CR6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/bcr6","volume":"1","author":"DF Easton","year":"1999","unstructured":"Easton DF (1999) How many more breast cancer predisposition genes are there? Breast Cancer Res 1:14\u201317","journal-title":"Breast Cancer Res"},{"key":"1006_CR7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"1006_CR8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/gcc.1223","volume":"33","author":"C Ghimenti","year":"2002","unstructured":"Ghimenti C, Sensi E, Presciuttini S et al (2002) Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast\/ovarian families negative for BRCA1 and BRCA2 alterations. Genes Chromosomes Cancer 33:235\u2013242","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"1006_CR9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10549-007-9799-x","volume":"111","author":"KL Gorringe","year":"2008","unstructured":"Gorringe KL, Choong DY, Visvader JE, Lindeman GJ, Campbell IG (2008) BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer. Breast Cancer Res Treat 111(3):505\u2013509","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1006_CR10","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1200\/JCO.1998.16.1.338","volume":"16","author":"PE Goss","year":"1998","unstructured":"Goss PE, Sierra S (1998) Current perspectives on radiation-induced breast cancer. J Clin Oncol 16(1):338\u2013347","journal-title":"J Clin Oncol"},{"issue":"3","key":"1006_CR11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/jhg.2009.6","volume":"54","author":"F Gu\u00e9nard","year":"2009","unstructured":"Gu\u00e9nard F, Labrie Y, Ouellette G, Beauparlant CJ, Durocher F, INHERIT BRCAs (2009) Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer. J Hum Genet 54(3):152\u2013161","journal-title":"J Hum Genet"},{"key":"1006_CR12","doi-asserted-by":"crossref","first-page":"14537","DOI":"10.1074\/jbc.C000881200","volume":"276","author":"R Hashizume","year":"2001","unstructured":"Hashizume R, Fukuda M, Maeda I et al (2001) The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276:14537\u201314540","journal-title":"J Biol Chem"},{"key":"1006_CR13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nrc1878","volume":"6","author":"I Irminger-Finger","year":"2006","unstructured":"Irminger-Finger I, Jefford CE (2006) Is there more to BARD1 than BRCA1? Nat Rev Cancer 6:382\u2013391","journal-title":"Nat Rev Cancer"},{"key":"1006_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(03)00387-2","volume":"200","author":"M Ishitobi","year":"2003","unstructured":"Ishitobi M, Miyoshi Y, Hasegawa S et al (2003) Mutational analysis of BARD1 in familial breast cancer patients in Japan. Cancer Lett 200:1\u20137","journal-title":"Cancer Lett"},{"issue":"1","key":"1006_CR15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10549-007-9537-4","volume":"107","author":"A Jakubowska","year":"2008","unstructured":"Jakubowska A, Cybulski C, Szyma\u0144ska A et al (2008) BARD1 and breast cancer in Poland. Breast Cancer Res Treat 107(1):119\u2013122","journal-title":"Breast Cancer Res Treat"},{"key":"1006_CR16","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1038\/sj.onc.1207427","volume":"23","author":"CE Jefford","year":"2004","unstructured":"Jefford CE, Feki A, Harb J, Krause KH, Irminger-Finger I (2004) Nuclear\u2013cytoplasmic translocation of BARD1 is linked to its apoptotic activity. Oncogene 23:3509\u20133520","journal-title":"Oncogene"},{"issue":"1","key":"1006_CR17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-008-0045-y","volume":"115","author":"SE Johnatty","year":"2009","unstructured":"Johnatty SE, Beesley J, Chen X et al (2009) The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case\u2013control and family analysis. Breast Cancer Res Treat 115(1):145\u2013150","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"1006_CR18","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1136\/jmg.2004.020669","volume":"41","author":"SM Karppinen","year":"2004","unstructured":"Karppinen SM, Heikkinen K, Rapakko K, Winqvist R (2004) Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer. J Med Genet 41(9):e114","journal-title":"J Med Genet"},{"issue":"11","key":"1006_CR19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmg.2006.041731","volume":"43","author":"SM Karppinen","year":"2006","unstructured":"Karppinen SM, Barkardottir RB, Backenhorn K et al (2006) Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1\/BRCA2 mutation-negative breast cancer but not in other malignancies. J Med Genet 43(11):856\u2013862","journal-title":"J Med Genet"},{"key":"1006_CR20","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719\u2013748","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"1006_CR21","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/jnci\/92.14.1126","volume":"92","author":"A-M Martin","year":"2000","unstructured":"Martin A-M, Weber BL (2000) Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst (Bethesda) 92(14):1126\u20131135","journal-title":"J Natl Cancer Inst (Bethesda)"},{"key":"1006_CR22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66\u201371","journal-title":"Science"},{"key":"1006_CR23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1471-2407-6-114","volume":"6","author":"VU Onay","year":"2006","unstructured":"Onay VU, Briollais L, Knight JA et al (2006) SNP\u2013SNP interactions in breast cancer susceptibility. BMC Cancer 6:114","journal-title":"BMC Cancer"},{"key":"1006_CR24","doi-asserted-by":"crossref","unstructured":"Ratajska M, Antoszewska E, Piskorz A et al (2011) Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Res Treat (Epub ahead of print)","DOI":"10.1007\/s10549-011-1403-8"},{"key":"1006_CR25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/jmg.2004.030049","volume":"42","author":"MK Sauer","year":"2005","unstructured":"Sauer MK, Andrulis IL (2005) Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer. J Med Genet 42:633\u2013638","journal-title":"J Med Genet"},{"key":"1006_CR26","doi-asserted-by":"crossref","unstructured":"Spurdle M, Marquart L, McGuffog L et al (2011) Common genetic variation at BARD1 is not associated with Breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 20:1032\u20131038","DOI":"10.1158\/1055-9965.EPI-10-0909"},{"issue":"7","key":"1006_CR27","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1371\/journal.pmed.0030217","volume":"3","author":"SN Stacey","year":"2006","unstructured":"Stacey SN, Sulem P, Johannsson OT et al (2006) The BARD1 Cys557Ser variant and breast cancer risk in Iceland. PLoS Med 3(7):e217","journal-title":"PLoS Med"},{"key":"1006_CR28","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM198705213162101","volume":"316","author":"M Swift","year":"1987","unstructured":"Swift M, Reitnauer PJ, Morrell D, Chase CL (1987) Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316:1289\u20131294","journal-title":"N Engl J Med"},{"key":"1006_CR29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1134\/S0012496606010182","volume":"406","author":"VA Tarasov","year":"2006","unstructured":"Tarasov VA, Aslanyan MM, Tsyrendorzhiyeva ES et al (2006) Genetically determined subdivision of human populations with respect to the risk of breast cancer in women. Dokl Biol Sci 406:66\u201369","journal-title":"Dokl Biol Sci"},{"key":"1006_CR30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/hmg\/7.2.195","volume":"7","author":"TH Thai","year":"1998","unstructured":"Thai TH, Du F, Tsan JT et al (1998) Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet 7:195\u2013202","journal-title":"Hum Mol Genet"},{"issue":"2","key":"1006_CR31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.ejhg.5201542","volume":"14","author":"P Vahteristo","year":"2006","unstructured":"Vahteristo P, Syrj\u00e4koski K, Heikkinen T et al (2006) BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition. Eur J Hum Genet 14(2):167\u2013172","journal-title":"Eur J Hum Genet"},{"key":"1006_CR32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789\u2013792","journal-title":"Nature"},{"key":"1006_CR33","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/ng1296-430","volume":"14","author":"LC Wu","year":"1996","unstructured":"Wu LC, Wang ZW, Tsan JT et al (1996) Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14:430\u2013440","journal-title":"Nat Genet"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-011-1006-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-011-1006-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-011-1006-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T16:24:46Z","timestamp":1560443086000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-011-1006-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,2]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["1006"],"URL":"https:\/\/doi.org\/10.1007\/s00432-011-1006-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,2]]}}}